928758-22-9

Upstream product

• 108-24-7 acetic anhydride 
• 21739-92-4 5-bromo-2-chlorobenzoic acid 
• 149965-40-2 5-bromo-2-chlorobenzyl alcohol 
• 879403-77-7 4-bromo-1-chloro-2-(phenoxymethyl)benzene 
• 1416165-07-5 (2S,3R,4S,5S,6R)-2-(4-chloro-3-(phenoxymethyl)phenyl)-6-(hydroxymethyl)-2-methoxytetrahydro-2H-pyran-3,4,5-triol 
• 1416165-08-6 (2S,3R,4S,5R,6R)-6-(acetoxymethyl)-2-(4-chloro-3-(phenoxymethyl)phenyl)-2-methoxytetrahydro-2H-pyran-3,4,5-triyl triacetate 

Downstream Products

• 928758-24-1 (2R,3R,4R,5S,6S)-2-(acetoxymethyl)-6-(3-(bromomethyl)-4-chlorophenyl)tetrahydro-2H-pyran-3,4,5-triyl triacetate 
• 1416165-36-0 (2R,3R,4R,5S,6S)-2-(acetoxymethyl)-6-(4-chloro-3-(4-propionylbenzyl)phenyl)tetrahydro-2H-pyran-3,4,5-triyl triacetate 
• 1416165-37-1 (2R,3R,4R,5S,6S)-2-(acetoxymethyl)-6-(4-chloro-3-(4-(1-(methoxyimino)-propyl)benzyl)phenyl)tetrahydro-2H-pyran-3,4,5-triyl triacetate 
• 1416164-53-8 1-(4-(2-chloro-5-((2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)benzyl)phenyl)-propan-1-one O-methyl oxime 
• 1426925-16-7 (2R,3R,4R,5S,6S)-2-(acetoxymethyl)-6-(4-chloro-3-((4-(1-(methoxyimino)methyl)cyclopropyl)benzyl)phenyl)tetrahydro-2H-pyran-3,4,5-triyl triacetate 
• 1426925-15-6 (2R,3R,4R,5S,6S)-2-(acetoxymethyl)-6-(4-chloro-3-(4-(1-formyl cyclopropyl)benzyl)phenyl)tetrahydro-2H-pyran-3,4,5-triyl triacetate 
• 1426925-13-4 1-(4-(2-chloro-5-((2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxylmethyl)tetrahydro-2H-pyran-2-yl)benzyl)phenyl)cyclopropanecarbaldehyde O-methyl oxime 

Relevant academic research and scientific papers

NOVEL SGLT INHIBITORS

The present invention relates to novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The invention also relates to the processes for the synt

NOVEL SGLT INHIBITORS

The present invention relates to novel compounds of Formula (I), their pharmaceutically acceptable derivatives, tautomeric forms, isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The invention also relates to the processes for the sy

NOVEL SGLT INHIBITORS

The present invention relates to novel compounds of Formula (I), their pharmaceutically acceptable derivatives, tautomeric forms, isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The invention also relates to the processes for the synthesis of novel compounds of Formula (I), their pharmaceutically acceptable derivatives, tautomeric forms, isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The present invention also provides pharmaceutical compositions comprising novel compounds of Formula (I) and methods of treating or preventing one or more conditions or diseases that may be regulated or normalized via inhibition of Sodium Glucose Cotransporter-2 (SGLT-2).

Processes for preparing of glucopyranosyl-substituted (ethynyl-benzyl)-benzene derivatives and intermediates thereof

The present invention relates to processes for preparing the compounds of general formula I, wherein the groups R1, R2 and R3 are defined according to claim 1 and to intermediates of said processes.